Yarrow Bioscience (YARW) Competitors

Yarrow Bioscience logo
$14.35 +0.00 (+0.03%)
As of 11:12 AM Eastern
This is a fair market value price provided by Massive. Learn more.

YARW vs. ADCT, BBOT, ANIK, UPB, and KROS

Should you buy Yarrow Bioscience stock or one of its competitors? Yarrow Bioscience's main competitors and comparable companies include ADC Therapeutics (ADCT), BridgeBio Oncology Therapeutics (BBOT), Anika Therapeutics (ANIK), Upstream Bio (UPB), and Keros Therapeutics (KROS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Yarrow Bioscience compare to ADC Therapeutics?

Yarrow Bioscience (NASDAQ:YARW) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, Yarrow Bioscience had 4 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Yarrow Bioscience and 1 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.75 beat Yarrow Bioscience's score of 0.35 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Yarrow Bioscience
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ADC Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Yarrow Bioscience currently has a consensus target price of $52.67, indicating a potential upside of 267.02%. ADC Therapeutics has a consensus target price of $5.00, indicating a potential upside of 271.75%. Given ADC Therapeutics' higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than Yarrow Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yarrow Bioscience
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
ADC Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Yarrow Bioscience has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yarrow Bioscience$570K67.22-$26.48M-$14.64N/A
ADC Therapeutics$81.36M2.33-$142.62M-$0.52N/A

ADC Therapeutics has a net margin of -95.73% compared to Yarrow Bioscience's net margin of -4,726.21%. ADC Therapeutics' return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Yarrow Bioscience-4,726.21% -28.99% -28.03%
ADC Therapeutics -95.73%N/A -28.26%

Yarrow Bioscience has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by insiders. Comparatively, 5.1% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Yarrow Bioscience beats ADC Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Yarrow Bioscience compare to BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Yarrow Bioscience's return on equity of -28.99% beat BridgeBio Oncology Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A -49.01% -43.18%
Yarrow Bioscience -4,726.21%-28.99%-28.03%

BridgeBio Oncology Therapeutics currently has a consensus price target of $19.33, indicating a potential upside of 971.10%. Yarrow Bioscience has a consensus price target of $52.67, indicating a potential upside of 267.02%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Yarrow Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Yarrow Bioscience
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, Yarrow Bioscience had 1 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 5 mentions for Yarrow Bioscience and 4 mentions for BridgeBio Oncology Therapeutics. Yarrow Bioscience's average media sentiment score of 0.35 beat BridgeBio Oncology Therapeutics' score of -0.36 indicating that Yarrow Bioscience is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Yarrow Bioscience
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

BridgeBio Oncology Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market.

Yarrow Bioscience has higher revenue and earnings than BridgeBio Oncology Therapeutics. Yarrow Bioscience is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.16N/A
Yarrow Bioscience$570K67.22-$26.48M-$14.64N/A

Summary

Yarrow Bioscience beats BridgeBio Oncology Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Yarrow Bioscience compare to Anika Therapeutics?

Yarrow Bioscience (NASDAQ:YARW) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Yarrow Bioscience has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Yarrow Bioscience currently has a consensus target price of $52.67, indicating a potential upside of 267.02%. Anika Therapeutics has a consensus target price of $19.00, indicating a potential upside of 39.50%. Given Yarrow Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Yarrow Bioscience is more favorable than Anika Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yarrow Bioscience
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Anika Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Anika Therapeutics has a net margin of -1.43% compared to Yarrow Bioscience's net margin of -4,726.21%. Anika Therapeutics' return on equity of 1.87% beat Yarrow Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Yarrow Bioscience-4,726.21% -28.99% -28.03%
Anika Therapeutics -1.43%1.87%1.39%

83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Yarrow Bioscience had 1 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for Yarrow Bioscience and 4 mentions for Anika Therapeutics. Yarrow Bioscience's average media sentiment score of 0.35 beat Anika Therapeutics' score of 0.15 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Yarrow Bioscience
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Anika Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Anika Therapeutics has higher revenue and earnings than Yarrow Bioscience. Anika Therapeutics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yarrow Bioscience$570K67.22-$26.48M-$14.64N/A
Anika Therapeutics$112.82M1.62-$10.88M-$0.13N/A

Summary

Anika Therapeutics beats Yarrow Bioscience on 8 of the 15 factors compared between the two stocks.

How does Yarrow Bioscience compare to Upstream Bio?

Yarrow Bioscience (NASDAQ:YARW) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Yarrow Bioscience has higher earnings, but lower revenue than Upstream Bio. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yarrow Bioscience$570K67.22-$26.48M-$14.64N/A
Upstream Bio$2.85M40.00-$143.44M-$3.02N/A

Yarrow Bioscience has a net margin of -4,726.21% compared to Upstream Bio's net margin of -5,712.33%. Yarrow Bioscience's return on equity of -28.99% beat Upstream Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Yarrow Bioscience-4,726.21% -28.99% -28.03%
Upstream Bio -5,712.33%-57.09%-54.69%

Yarrow Bioscience has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

Yarrow Bioscience presently has a consensus price target of $52.67, indicating a potential upside of 267.02%. Upstream Bio has a consensus price target of $26.67, indicating a potential upside of 1,182.05%. Given Upstream Bio's higher probable upside, analysts plainly believe Upstream Bio is more favorable than Yarrow Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yarrow Bioscience
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

In the previous week, Upstream Bio had 5 more articles in the media than Yarrow Bioscience. MarketBeat recorded 10 mentions for Upstream Bio and 5 mentions for Yarrow Bioscience. Upstream Bio's average media sentiment score of 0.54 beat Yarrow Bioscience's score of 0.35 indicating that Upstream Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Yarrow Bioscience
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Upstream Bio
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

83.8% of Yarrow Bioscience shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by company insiders. Comparatively, 16.5% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Yarrow Bioscience beats Upstream Bio on 8 of the 14 factors compared between the two stocks.

How does Yarrow Bioscience compare to Keros Therapeutics?

Yarrow Bioscience (NASDAQ:YARW) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Yarrow Bioscience has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Keros Therapeutics has a net margin of -256.60% compared to Yarrow Bioscience's net margin of -4,726.21%. Keros Therapeutics' return on equity of -21.85% beat Yarrow Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Yarrow Bioscience-4,726.21% -28.99% -28.03%
Keros Therapeutics -256.60%-21.85%-19.83%

Yarrow Bioscience currently has a consensus price target of $52.67, suggesting a potential upside of 267.02%. Keros Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 66.67%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, equities analysts clearly believe Yarrow Bioscience is more favorable than Keros Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yarrow Bioscience
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Keros Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57

In the previous week, Keros Therapeutics had 2 more articles in the media than Yarrow Bioscience. MarketBeat recorded 7 mentions for Keros Therapeutics and 5 mentions for Yarrow Bioscience. Keros Therapeutics' average media sentiment score of 0.70 beat Yarrow Bioscience's score of 0.35 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Yarrow Bioscience
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Keros Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Keros Therapeutics has higher revenue and earnings than Yarrow Bioscience. Keros Therapeutics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yarrow Bioscience$570K67.22-$26.48M-$14.64N/A
Keros Therapeutics$40.76M5.78$87.01M-$2.82N/A

83.8% of Yarrow Bioscience shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Keros Therapeutics beats Yarrow Bioscience on 10 of the 16 factors compared between the two stocks.

Get Yarrow Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for YARW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YARW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

YARW vs. The Competition

MetricYarrow BioscienceBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$38.25M$3.95B$7.50B$11.74B
Dividend YieldN/A3.63%2.47%4.65%
P/E Ratio-0.9823.8233.0329.92
Price / Sales67.2415.578.115.47
Price / CashN/A22.7220.8521.62
Price / Book0.144.194.423.71
Net Income-$26.48M-$24.02M$3.51B$394.40M
7 Day Performance-26.88%-6.32%-5.15%-5.09%
1 Month Performance-28.16%-8.20%-6.09%-7.58%
1 Year PerformanceN/A-4.50%-1.10%-7.23%

Yarrow Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
YARW
Yarrow Bioscience
2.3225 of 5 stars
$14.35
+0.0%
$52.67
+266.9%
N/A$38.25M$570KN/A30
ADCT
ADC Therapeutics
2.128 of 5 stars
$1.50
-1.0%
$5.00
+234.4%
-66.3%$190.87M$81.36MN/A191
BBOT
BridgeBio Oncology Therapeutics
3.7861 of 5 stars
$2.37
+7.8%
$19.33
+715.4%
N/A$190.81MN/AN/A88
ANIK
Anika Therapeutics
4.0825 of 5 stars
$13.92
+3.3%
$22.00
+58.0%
+40.8%$186.26M$112.82MN/A235
UPB
Upstream Bio
3.5096 of 5 stars
$3.37
-0.4%
$26.67
+692.5%
-91.9%$184.25M$2.85MN/A75

Related Companies and Tools


This page (NASDAQ:YARW) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners